Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
1.210
-0.100 (-7.63%)
Jan 21, 2025, 4:00 PM EST - Market closed
Cue Biopharma Revenue
Cue Biopharma had revenue of $3.34M in the quarter ending September 30, 2024, with 58.86% growth. This brings the company's revenue in the last twelve months to $9.53M, up 149.53% year-over-year. In the year 2023, Cue Biopharma had annual revenue of $5.49M with 340.96% growth.
Revenue (ttm)
$9.53M
Revenue Growth
+149.53%
P/S Ratio
6.29
Revenue / Employee
$179,849
Employees
53
Market Cap
76.65M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
CUE News
- 7 weeks ago - Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Cue Biopharma Announces Strategic Organizational Transition - GlobeNewsWire
- 2 months ago - Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting - GlobeNewsWire
- 3 months ago - Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - GlobeNewsWire
- 4 months ago - Cue Biopharma Announces Pricing of $12.0 Million Public Offering - GlobeNewsWire
- 4 months ago - Cue Biopharma Announces Proposed Public Offering - GlobeNewsWire